GSK
787 hedge funds and large institutions have $11B invested in GSK in 2018 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 260 increasing their positions, 294 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
0.01% less ownership
Funds ownership: 4.43% → 4.42% (-0.01%)
1% less capital invested
Capital invested by funds: $11.1B → $11B (-$60.7M)
12% less repeat investments, than reductions
Existing positions increased: 260 | Existing positions reduced: 294
Holders
787
Holding in Top 10
15
Calls
$123M
Puts
$87.4M
Top Buyers
| 1 | +$215M | |
| 2 | +$32.4M | |
| 3 | +$29.1M | |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$25.4M |
| 5 |
Morgan Stanley
New York
|
+$24M |
Top Sellers
| 1 | -$152M | |
| 2 | -$70.8M | |
| 3 | -$39.6M | |
| 4 |
Millennium Management
New York
|
-$30.4M |
| 5 |
CIM
Confluence Investment Management
St. Louis,
Missouri
|
-$22M |